Initiative for a new diabetes therapeutic approach in a Mediterranean country: The INDEED study

Current Medical Research and Opinion

Volumn 25, Issue 8, 2009, Pages 1931-1940

  Athyros, V G ^a   Hatzitolios, A ^a   Karagiannis, A ^a   Didangelos, T P ^a   Iliadis, F ^a   Dolgyras, S ^b   Vosnakidis, T ^c   Vasiliadis, P ^d   Malias, I ^e   Tziomalos, K ^f   Samouilidou, M ^g   Mikhailidis, D P ^f  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Edessa Hospital   (Greece)

^c Agios Dimitrios Hospital   (Greece)

^d Psychiatric Hospital   (Greece)

^e Serres Hospital   (Greece)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g Health Centre of Agios Nikolaos   (Greece)

Author keywords

Awareness; Best practice; Cardiovascular risk calculation; Cardiovascular risk management; Diabetes mellitus; Public health

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CLOPIDOGREL; EZETIMIBE; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; SULFONYLUREA DERIVATIVE;

ADULT; ARTICLE; AWARENESS; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONTROLLED STUDY; EVIDENCE BASED PRACTICE; FEMALE; FOLLOW UP; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; RISK MANAGEMENT; SCORING SYSTEM; SOUTHERN EUROPE; STROKE;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIFFUSION OF INNOVATION; FEMALE; GREECE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PILOT PROJECTS; PROSPECTIVE STUDIES; RISK REDUCTION BEHAVIOR;

EID: 67650837927     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903073035     Document Type: Article

References (48)

1. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-93
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1999;352:837-53
3. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91
4. Gaede P, Valentine WJ, Palmer AJ, et al. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care 2008;31:1510-15
5. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72
6. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
7. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008;358:2630-3
8. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care 2008;31(Suppl 1):S12-54
9. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004;291:335-42
10. Hatzitolios AI, Athyros VG, Karagiannis A, et al.; for the IMPROVE Collaborative Group. Implementation of strategy for the management of overt dyslipidemia: The IMPROVE-dyslipidemia study. Int J Cardiol 2009;134:322-9
11. Athyros VG, Karagiannis A, Hatzitolios AI, et al. Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study. Curr Med Res Opin 2009;25:971-80
12. Karagiannis A, Hatzitolios AI, Athyros VG, et al.; for the IMPULSION Collaborative Group. IMPlementation of gUideLines for the management of arterial hypertenSION. The IMPULSION study. Open Cardiovasc Med J 2009 (in press)
13. Expert Committee on the Diagnosis and the Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and the classification of diabetes mellitus. Diabetes Care 1997;20:1183-97
14. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
15. Panagiotakos DB, Pitsavos C, Stefanadis C. Dietary patterns: a Mediterranean diet score and its relation to clinical and biological markers of cardiovascular disease risk. Nutr Metab Cardiovasc Dis 2006;16:559-68
16. Panagiotakos DB, Pitsavos C, Arvaniti F, et al. Adherence to the Mediterranean food pattern predicts the prevalence of hypertension, hypercholesterolemia, diabetes and obesity, among healthy adults; the accuracy of the MedDietScore. Prev Med 2007;44:335-40
17. Panagiotakos DB, Pitsavos C, Chrysohou C, et al. The effect of clinical characteristics and dietary habits on the relationship between education status and 5-year incidence of cardiovascular disease: the ATTICA study. Eur J Nutr 2008;47:258-65
18. Stevens R, Adler A, Gray A, et al. Life-expectancy projection by modelling and computer simulation (UKPDS 46). Diab Res Clin Pract 2000;50(Suppl 3):S5-13
19. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
20. The global challenge of diabetes (Editorial). Lancet 2008;371:1723
21. Burns N, Finucane FM, Hatunic M, et al. Early-onset type 2 diabetes in obese white subjects is characterised by a marked defect in beta cell insulin secretion, severe insulin resistance and a lack of response to aerobic exercise training. Diabetologia 2007;50:1500-8
22. Schmittdiel JA, Uratsu CS, Karter AJ, et al. Why don't diabetes patients achieve recommended risk factor targets? Poor adherence versus lack of treatment intensification. J Gen Intern Med 2008;23:588-94
23. Ford ES, Capewell S. Coronary heart disease mortality among young adults in the US from 1980 through 2002. Concealed leveling of mortality rates. J Am Coll Cardiol 2007;50:2128-32
24. Greenland P, Lloyd-Jones D. Time to end the mixed - and often incorrect - messages about prevention and treatment of atherosclerotic cardiovascular disease. J Am Coll Cardiol 2007;50:2133-5
25. O'Flaherty M, Ford E, Allender S, et al. Coronary heart disease trends in England and Wales from 1984 to 2004: concealed leveling of mortality rates among young adults. Heart 2008;94:178-81
26. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al; METS-GREECE Collaborative Group. Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin 2004;20:1691-701
27. Zazpe I, Sanchez-Tainta A, Estruch R, et al. A large randomized individual and group intervention conducted by registered dietitians increased adherence to Mediterranean-type diets: the PREDIMED study. J Am Diet Assoc 2008;108:1134-44
28. Estruch R, Martínez-González MA, Corella D, et al.; PREDIMED Study Investigators. Effects of a Mediterranean-style diet on cardiovascular risk factors: a randomized trial. Ann Intern Med 2006;145:1-11
29. Bellary S, O'Hare JP, Raymond NT, et al.; UKADS Study Group. Enhanced diabetes care to patients of south Asian ethnic origin (the United Kingdom Asian Diabetes Study): a cluster randomised controlled trial. Lancet 2008;371:1769-76
30. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
31. Duckworth W, Abraira C, Moritz T, et al.; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39
32. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
33. Gaede P, Pedersen O. Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. Diabetes 2004;53(Suppl 3):S39-47
34. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96
35. Collins R, Armitage J, Parish S, et al.; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16
36. Athyros VG, Papageorgiou AA, Symeonidis AN, et al.; GREACE Study Collaborative Group. Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology 2003;54:679-90
37. Hunsicker LG. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control. J Manag Care Pharm 2004;10(Suppl A):S12-17
38. Weir MR. Effects of renin-angiotensin system inhibition on endorgan protection: can we do better? Clin Ther 2007;29:1803-24
39. Tomita H, Kawamoto R, Tabara Y, et al. Blood pressure is the main determinant of the reflection wave in patients with type 2 diabetes. Hypertens Res 2008;31:493-9
40. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998;351:1755-62
41. Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997;350:757-64
42. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9
43. Fonarow GC, Gawlinski A, Moughrabi S, et al. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001;87:819-22
44. Kotseva K, Wood D, Guy De Backer G, et al.; for the EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009;373:929-40
45. Zannad F, Agabiti-Rosei E. Profile of patients with type 2 diabetes in France and Italy. J Hypertens 2008;26(Suppl 3):S3-6
46. Ott P, Benke I, Stelzer J, et al. ["Diabetes in Germany" (DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice] [Article in German] Dtsch Med Wochenschr 2009;134:291-7
47. McDonald M, Hertz RP, Unger AN, et al. Prevalence, awareness, and management of hypertension, dyslipidemia, and diabetes among United States adults aged 65 and older. J Gerontol A Biol Sci Med Sci 2009;64:256-63
48. Steinberg BA, Bhatt DL, Mehta S, et al. Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease. Am Heart J 2008;156:719-27